INCE Capital congratulates Dr. Shanshan Xu, Founder and CEO of Bambusa Therapeutics, and the entire team on this important milestone and the beginning of an exciting new chapter as a Nasdaq-listed company!
On October 30, 2026, Bambusa Therapeutics, Inc. (Nasdaq: BBTX) (“Bambusa Therapeutics” or “Bambusa”), a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, began trading on the Nasdaq Global Select Market under the ticker symbol BBTX, following the successful pricing of its upsized initial public offering.
The initial public offering comprised 10,555,555 shares of common stock at a public offering price of US$16.00 per share. The gross proceeds to Bambusa from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Bambusa, are expected to be $168,888,880. Bambusa also granted the underwriters a 30-day option to purchase up to an additional 1,583,333 shares.
Congratulations again to Bambusa Therapeutics on its NASDAQ IPO!
About Bambusa Therapeutics
Bambusa Therapeutics is a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies designed to redefine standards of care in immunology and inflammation and fundamentally improve patient quality of life. The company combines third-party, advanced antibody engineering and clinically and commercially validated biologic pathways into a single molecule formulated for high-concentration subcutaneous delivery to improve durability, convenience, and clinical differentiation beyond the current capabilities of existing monotherapies. Its pipeline includes BBT001, a bispecific antibody targeting IL-4Rα and IL-31, in clinical development for atopic dermatitis and other inflammatory skin diseases; BBT002, a bispecific antibody targeting IL-4Rα and IL-5 in clinical development for Type 2 inflammatory disorders; and preclinical programs BBT003 and BBT004 focused on gastroenterology and autoantibody-driven autoimmune diseases, respectively.
Original Source
https://bambusatx.com/bambusa-therapeutics-announces-pricing-of-upsized-initial-public-offering/
